Compositions and methods for treating bladder conditions
US-2024165134-A1 · May 23, 2024 · US
US9044477B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9044477-B2 |
| Application number | US-95462907-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 12, 2007 |
| Priority date | Dec 12, 2007 |
| Publication date | Jun 2, 2015 |
| Grant date | Jun 2, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
Opening claim text (preview).
We claim: 1. A pharmaceutical composition comprising a botulinum neurotoxin, albumin and a viscous carrier for the botulinum neurotoxin, wherein the viscous carrier comprises a cross-linked hyaluronic acid having a molecular weight ranging from about 10,000 daltons to about 200,000 daltons, a crosslinking density ranging from about 5% to about 10%, present in a range from about 1% to about 4% (w/v) of the pharmaceutical composition, wherein the pharmaceutical composition having a v…
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.